{
    "id": "d82910d95d",
    "level": "sentence",
    "abstract": [
        {
            "text": "Objective: Agonists of \u03b17-nicotinic acetylcholine receptors (nAChRs) have been developed as potential therapeutic drugs for neuropsychiatric diseases such as schizophrenia and Alzheimer's disease. ",
            "paragraph_rank": 1,
            "section_rank": 0
        },
        {
            "text": "Positron emission tomography (PET) is a noninvasive brain imaging technique to measure receptor occupancy in the living human brain. ",
            "paragraph_rank": 1,
            "section_rank": 0
        },
        {
            "text": "Although much effort has been expended to create specific PET radioligands for \u03b17-nAChRs in the brain, only 4-[ 11 C]methylphenyl-1,4-diazabicyclo[3.2.2.]nonane-4-carboxylate ([ 11 C]CHIBA-1001) is currently available for clinical studies. ",
            "paragraph_rank": 1,
            "section_rank": 0
        },
        {
            "text": "In contrast, two 5-hydroxytryptamine-3 (5-HT3) receptor antagonists, tropisetron and ondansetron, have been used to treat patients with chemotherapy-induced or postoperative nausea and vomiting. ",
            "paragraph_rank": 1,
            "section_rank": 0
        },
        {
            "text": "Furthermore, tropisetron, but not ondansetron, possesses high affinity for \u03b17-nAChRs. ",
            "paragraph_rank": 1,
            "section_rank": 0
        },
        {
            "text": "In the present study, we evaluated the receptor occupancy in the human brain after a single oral administration of tropisetron and ondansetron using [ 11 C]CHIBA-1001 and PET. ",
            "paragraph_rank": 1,
            "section_rank": 0
        },
        {
            "text": "Methods: Two serial dynamic PET scans using [ 11 C]CHIBA-1001 in healthy non-smoking male subjects were performed before and after receiving an oral administration of these medications. ",
            "paragraph_rank": 1,
            "section_rank": 0
        },
        {
            "text": "Results: A single oral administration of tropisetron, but not ondansetron, decreased the total distribution volume of [ 11 C]CHIBA-1001 in the human brain. ",
            "paragraph_rank": 1,
            "section_rank": 0
        },
        {
            "text": "Conclusion: This study shows that tropisetron, but not ondansetron, could bind to \u03b17-nAChRs in the human brain after a single oral administration. ",
            "paragraph_rank": 1,
            "section_rank": 0
        },
        {
            "text": "Therefore, [ 11 C]CHIBA-1001 may be a useful PET radioligand to measure the occupancy of \u03b17-nAChRs in the human brain.",
            "paragraph_rank": 1,
            "section_rank": 0
        }
    ],
    "body_text": [
        {
            "text": "INTRODUCTION",
            "section_rank": 1
        },
        {
            "text": "The main subtypes of nicotinic acetylcholine receptors (nAChRs) in the central nervous system are the \u03b14\u03b22 and \u03b17 subtypes. ",
            "section": "INTRODUCTION",
            "paragraph_rank": 2,
            "section_rank": 1
        },
        {
            "text": "\u03b17-nAChRs have lower affinity for acetylcholine compared with \u03b14\u03b22 nAChRs 1) and demonstrate a high capacity for calcium influx that equals or exceeds N-methyl-D-aspartate receptors, suggesting its significant role in regulating a variety of downstream signaling events.",
            "section": "INTRODUCTION",
            "paragraph_rank": 2,
            "section_rank": 1,
            "ref_spans": [
                {
                    "start": 74,
                    "end": 76,
                    "type": "bibr",
                    "ref_id": "b0",
                    "text": "1)"
                }
            ]
        },
        {
            "text": "2) Accumulating evidence suggests that \u03b17-nAChRs play a role in the pathophysiology of several neu-ropsychiatric diseases such as schizophrenia, Alzheimer's disease, attention deficit hyperactivity disorder, and Parkinson's disease. ",
            "section": "INTRODUCTION",
            "paragraph_rank": 3,
            "section_rank": 1
        },
        {
            "text": "[3][4][5][6][7] A number of pharmaceutical programs have been developing selective agonists and positive allosteric modulators of \u03b17-nAChRs [7][8][9][10][11][12][13][14][15] as potential therapeutic drugs for these diseases. ",
            "section": "INTRODUCTION",
            "paragraph_rank": 3,
            "section_rank": 1,
            "ref_spans": [
                {
                    "start": 0,
                    "end": 3,
                    "type": "bibr",
                    "text": "[3]"
                },
                {
                    "start": 3,
                    "end": 6,
                    "type": "bibr",
                    "ref_id": "b3",
                    "text": "[4]"
                },
                {
                    "start": 6,
                    "end": 9,
                    "type": "bibr",
                    "ref_id": "b4",
                    "text": "[5]"
                },
                {
                    "start": 9,
                    "end": 12,
                    "type": "bibr",
                    "ref_id": "b5",
                    "text": "[6]"
                },
                {
                    "start": 12,
                    "end": 15,
                    "type": "bibr",
                    "ref_id": "b6",
                    "text": "[7]"
                },
                {
                    "start": 140,
                    "end": 143,
                    "type": "bibr",
                    "ref_id": "b6",
                    "text": "[7]"
                },
                {
                    "start": 143,
                    "end": 146,
                    "type": "bibr",
                    "ref_id": "b7",
                    "text": "[8]"
                },
                {
                    "start": 146,
                    "end": 149,
                    "type": "bibr",
                    "ref_id": "b8",
                    "text": "[9]"
                },
                {
                    "start": 149,
                    "end": 153,
                    "type": "bibr",
                    "ref_id": "b9",
                    "text": "[10]"
                },
                {
                    "start": 153,
                    "end": 157,
                    "type": "bibr",
                    "ref_id": "b10",
                    "text": "[11]"
                },
                {
                    "start": 157,
                    "end": 161,
                    "type": "bibr",
                    "ref_id": "b11",
                    "text": "[12]"
                },
                {
                    "start": 161,
                    "end": 165,
                    "type": "bibr",
                    "ref_id": "b12",
                    "text": "[13]"
                },
                {
                    "start": 165,
                    "end": 169,
                    "type": "bibr",
                    "ref_id": "b13",
                    "text": "[14]"
                },
                {
                    "start": 169,
                    "end": 173,
                    "type": "bibr",
                    "ref_id": "b14",
                    "text": "[15]"
                }
            ]
        },
        {
            "text": "However, it is difficult to evaluate the potential dose regimens of these drugs for treating these diseases. ",
            "section": "INTRODUCTION",
            "paragraph_rank": 3,
            "section_rank": 1
        },
        {
            "text": "Positron emission tomography (PET) is one of the brain imaging techniques that can measure biochemical and physiological information in the living human brain. ",
            "section": "INTRODUCTION",
            "paragraph_rank": 3,
            "section_rank": 1
        },
        {
            "text": "The distribution and density of receptors in the living human brain can be visualized noninvasively by PET using receptor-specific radioligands, and the receptor-radioligand binding can be quantified by appropriate tracer kinetic models. ",
            "section": "INTRODUCTION",
            "paragraph_rank": 3,
            "section_rank": 1
        },
        {
            "text": "16,17) Much effort has been devoted to visualize \u03b17-nAChRs in the human brain by PET, but the development of specific radioligands that depict \u03b17-nAChRs has been hampered by the relatively low levels of \u03b17-nAChRs in the brain. ",
            "section": "INTRODUCTION",
            "paragraph_rank": 3,
            "section_rank": 1,
            "ref_spans": [
                {
                    "start": 0,
                    "end": 3,
                    "type": "bibr",
                    "ref_id": "b15",
                    "text": "16,"
                },
                {
                    "start": 3,
                    "end": 6,
                    "type": "bibr",
                    "ref_id": "b16",
                    "text": "17)"
                }
            ]
        },
        {
            "text": "[18][19][20] Generally, \u03b1-bungarotoxin and methyllycaconitine (MLA) are well known to be specific and potent \u03b17-nAChR antagonists, but due to their large molecular weights, they have difficulty passing through the blood-brain barrier, which makes them unfavorable as PET radioligands. ",
            "section": "INTRODUCTION",
            "paragraph_rank": 3,
            "section_rank": 1,
            "ref_spans": [
                {
                    "start": 0,
                    "end": 4,
                    "type": "bibr",
                    "ref_id": "b17",
                    "text": "[18]"
                },
                {
                    "start": 4,
                    "end": 8,
                    "type": "bibr",
                    "ref_id": "b18",
                    "text": "[19]"
                },
                {
                    "start": 8,
                    "end": 12,
                    "type": "bibr",
                    "ref_id": "b19",
                    "text": "[20]"
                }
            ]
        },
        {
            "text": "[21][22][23] Consequently, a number of compounds have been developed and evaluated as potential PET radioligands for \u03b17-nAChRs. ",
            "section": "INTRODUCTION",
            "paragraph_rank": 3,
            "section_rank": 1,
            "ref_spans": [
                {
                    "start": 0,
                    "end": 4,
                    "type": "bibr",
                    "ref_id": "b20",
                    "text": "[21]"
                },
                {
                    "start": 4,
                    "end": 8,
                    "type": "bibr",
                    "ref_id": "b21",
                    "text": "[22]"
                },
                {
                    "start": 8,
                    "end": 12,
                    "type": "bibr",
                    "ref_id": "b23",
                    "text": "[23]"
                }
            ]
        },
        {
            "text": "6,24) However, only Potent 5-hydroxytryptamine-3 (5-HT 3 ) receptor antagonists such as tropisetron and ondansetron have been used to treat patients with chemotherapy-induced or postoperative nausea and vomiting. ",
            "section": "INTRODUCTION",
            "paragraph_rank": 3,
            "section_rank": 1,
            "ref_spans": [
                {
                    "start": 0,
                    "end": 2,
                    "type": "bibr",
                    "ref_id": "b5",
                    "text": "6,"
                },
                {
                    "start": 2,
                    "end": 5,
                    "type": "bibr",
                    "ref_id": "b25",
                    "text": "24)"
                }
            ]
        },
        {
            "text": "[28][29][30] Tropisetron is a partial agonist of \u03b17-nAChRs with high affinity (Ki=6.9 nM), whereas ondansetron has low affinity for \u03b17-nAChRs (Ki\uff1e10,000 nM) ( Table 1). ",
            "section": "INTRODUCTION",
            "paragraph_rank": 3,
            "section_rank": 1,
            "ref_spans": [
                {
                    "start": 0,
                    "end": 4,
                    "type": "bibr",
                    "ref_id": "b29",
                    "text": "[28]"
                },
                {
                    "start": 4,
                    "end": 8,
                    "type": "bibr",
                    "ref_id": "b30",
                    "text": "[29]"
                },
                {
                    "start": 8,
                    "end": 12,
                    "type": "bibr",
                    "ref_id": "b32",
                    "text": "[30]"
                },
                {
                    "start": 159,
                    "end": 167,
                    "type": "table",
                    "ref_id": "tab_0",
                    "text": "Table 1)"
                }
            ]
        },
        {
            "text": "31,32) Both drugs lack affinity for \u03b14\u03b22-nAChRs (Table 1). ",
            "section": "INTRODUCTION",
            "paragraph_rank": 3,
            "section_rank": 1,
            "ref_spans": [
                {
                    "start": 0,
                    "end": 3,
                    "type": "bibr",
                    "ref_id": "b33",
                    "text": "31,"
                },
                {
                    "start": 3,
                    "end": 6,
                    "type": "bibr",
                    "ref_id": "b34",
                    "text": "32)"
                },
                {
                    "start": 48,
                    "end": 56,
                    "type": "table",
                    "ref_id": "tab_0",
                    "text": "(Table 1"
                }
            ]
        },
        {
            "text": "In the present study, we investigated whether a single administration of tropisetron or ondansetron would bind to \u03b17-nAChRs in the intact human brain using [ 11 C]CHIBA-1001 and PET.",
            "section": "INTRODUCTION",
            "paragraph_rank": 3,
            "section_rank": 1
        },
        {
            "text": "METHODS",
            "section_rank": 2
        },
        {
            "text": "Subjects",
            "section_rank": 3
        },
        {
            "text": "This study was approved by the Ethics Committees of Tokyo Metropolitan Institute of Gerontology (Tokyo, Japan) and Chiba University Graduate School of Medi-cine (Chiba, Japan). ",
            "section": "Subjects",
            "paragraph_rank": 4,
            "section_rank": 3
        },
        {
            "text": "Twelve healthy non-smoking male volunteers participated in the study (mean age, 22.2 years; SD, 3.0; range, 20-31). ",
            "section": "Subjects",
            "paragraph_rank": 4,
            "section_rank": 3
        },
        {
            "text": "Written informed consent was obtained from each subject after the procedures had been fully explained. ",
            "section": "Subjects",
            "paragraph_rank": 4,
            "section_rank": 3
        },
        {
            "text": "None of the subjects had any neurological or psychological findings, and none showed any abnormalities on the brain magnetic resonance imaging scan taken between the two PET scans. ",
            "section": "Subjects",
            "paragraph_rank": 4,
            "section_rank": 3
        },
        {
            "text": "None had been receiving any medications of any kind, and none had a history of alcoholism. ",
            "section": "Subjects",
            "paragraph_rank": 4,
            "section_rank": 3
        },
        {
            "text": "]CHIBA-1001-PET scans, one before and one after oral administration of tropisetron or ondansetron. ",
            "section": "Subjects",
            "paragraph_rank": 4,
            "section_rank": 3
        },
        {
            "text": "The second PET scan took place 3-3.5 hours after taking the medication to coincide with the peak plasma level. ",
            "section": "Subjects",
            "paragraph_rank": 4,
            "section_rank": 3
        },
        {
            "text": "After oral administration of a single dose of tropisetron (5 mg), blood concentration reaches a peak in approximately 3.4 hours in healthy Japanese male subjects. ",
            "section": "Subjects",
            "paragraph_rank": 4,
            "section_rank": 3
        },
        {
            "text": "33) Accordingly, we collected venous blood samples (except from one volunteer for technical reasons) just before tracer injection of the second PET scan to monitor the tropisetron concentration. ",
            "section": "Subjects",
            "paragraph_rank": 4,
            "section_rank": 3
        },
        {
            "text": "Plasma tropisetron concentration was measured by high performance liquid chromatography (HPLC) followed by tandem mass spectrometry. ",
            "section": "Subjects",
            "paragraph_rank": 4,
            "section_rank": 3
        },
        {
            "text": "In the case of ondansetron, the second PET scan occurred 2 hours after administration, as the concentration in blood reaches its peak in approximately 2 hours after oral administration of a single dose of ondansetron (4 mg) in healthy Japanese male subjects. ",
            "section": "Subjects",
            "paragraph_rank": 4,
            "section_rank": 3
        },
        {
            "text": "34) Volunteers were randomly administered either tropisetron (5, 10, or 20 mg, n=3 for each dose; Navoban \u24c7 , Novartis Pharma KK, Tokyo, Japan) or ondansetron (8 mg, n=3; Zofran \u24c7 , GlaxoSmithKline KK, Tokyo, Japan). ",
            "section": "Subjects",
            "paragraph_rank": 4,
            "section_rank": 3,
            "ref_spans": [
                {
                    "start": 0,
                    "end": 3,
                    "type": "bibr",
                    "ref_id": "b36",
                    "text": "34)"
                }
            ]
        },
        {
            "text": "PET was performed at the Positron Medical Center, Tokyo Metropolitan Institute of Gerontology with a SET 2400W scanner (Shimadzu Co., Kyoto, Japan). ",
            "section": "Subjects",
            "paragraph_rank": 4,
            "section_rank": 3
        },
        {
            "text": "35) The spatial resolution was 4.4 mm full width at half maximum in the transverse direction and 6.5 mm full width at half maximum in the axial direction. ",
            "section": "Subjects",
            "paragraph_rank": 4,
            "section_rank": 3,
            "ref_spans": [
                {
                    "start": 0,
                    "end": 3,
                    "type": "bibr",
                    "ref_id": "b37",
                    "text": "35)"
                }
            ]
        },
        {
            "text": "A transmission scan was performed with a rotating 68 Ga/ 68 Ge rod source for 5 minutes for attenuation correction before the administration of [ 11 C]CHIBA-1001, which was prepared as described previously. ",
            "section": "Subjects",
            "paragraph_rank": 4,
            "section_rank": 3
        },
        {
            "text": "25) A dynamic series of decay-corrected PET data acquisition data were collected in the two-dimensional mode for 90 minutes starting at the time of the intravenous bolus injection of [ 11 C]CHIBA-1001 (injected dose, 518\u00b153 MBq; specific activity, 42.7\u00b122.6 TBq/mmol). ",
            "section": "Subjects",
            "paragraph_rank": 4,
            "section_rank": 3,
            "ref_spans": [
                {
                    "start": 0,
                    "end": 3,
                    "type": "bibr",
                    "ref_id": "b26",
                    "text": "25)"
                }
            ]
        },
        {
            "text": "The frame arrangement was 10 seconds\u00d76 frames, 30 seconds\u00d73 frames, 60 seconds\u00d75 frames, 150 seconds\u00d75 frames, and 300 seconds\u00d714 frames. ",
            "section": "Subjects",
            "paragraph_rank": 4,
            "section_rank": 3
        },
        {
            "text": "The dynamic image was reconstructed with a filtered back-projection algorithm using a Butterworth filter (1.25 cycles/cm, order 2); the image matrix was 128\u00d7128\u00d731, and the voxel size was 2\u00d72\u00d76.25 mm. ",
            "section": "Subjects",
            "paragraph_rank": 4,
            "section_rank": 3
        },
        {
            "text": "Each subject was placed in a supine position with eyes closed. ",
            "section": "Subjects",
            "paragraph_rank": 4,
            "section_rank": 3
        },
        {
            "text": "Immediately after the bolus injection, 12 arterial blood samples were collected at 10-second intervals over 2 minutes, and the remaining 14 samples were collected at longer intervals, for a total of 26 samples. ",
            "section": "Subjects",
            "paragraph_rank": 4,
            "section_rank": 3
        },
        {
            "text": "All samples were manually drawn. ",
            "section": "Subjects",
            "paragraph_rank": 4,
            "section_rank": 3
        },
        {
            "text": "Plasma was separated, weighed and measured for radioactivity with a sodium-iodide well scintillation counter. ",
            "section": "Subjects",
            "paragraph_rank": 4,
            "section_rank": 3
        },
        {
            "text": "Six samples collected at 3, 10, 20, 30, 40, and 60 minutes were further processed by HPLC for metabolite analysis. ",
            "section": "Subjects",
            "paragraph_rank": 4,
            "section_rank": 3
        },
        {
            "text": "25) Data Analysis",
            "section": "Subjects",
            "paragraph_rank": 4,
            "section_rank": 3,
            "ref_spans": [
                {
                    "start": 0,
                    "end": 3,
                    "type": "bibr",
                    "ref_id": "b26",
                    "text": "25)"
                }
            ]
        },
        {
            "text": "Image manipulations were performed using the \"Dr. View\", version 5.2 medical image processing application package (AJS Inc., Tokyo, Japan). ",
            "section": "Subjects",
            "paragraph_rank": 5,
            "section_rank": 3,
            "entity_spans": [
                {
                    "start": 46,
                    "end": 54,
                    "type": "software",
                    "rawForm": "Dr. View",
                    "resp": "#annotator20",
                    "used": true,
                    "id": "d82910d95d-software-0",
                    "cert": "0.7"
                },
                {
                    "start": 65,
                    "end": 68,
                    "type": "version",
                    "rawForm": "5.2",
                    "resp": "#annotator20",
                    "id": "#d82910d95d-software-0"
                },
                {
                    "start": 115,
                    "end": 122,
                    "type": "publisher",
                    "rawForm": "AJS Inc",
                    "resp": "#curator",
                    "id": "#d82910d95d-software-0"
                }
            ]
        },
        {
            "text": "Regions of interest (ROIs) were defined over the frontal, temporal, parietal, and occipital cortices, head of the caudate nucleus, putamen, and cerebellum with reference to a coregistered magnetic resonance image, which served as an anatomical guide. ",
            "section": "Subjects",
            "paragraph_rank": 5,
            "section_rank": 3
        },
        {
            "text": "The total distribution volume (VT) of [ 11 C]CHIBA-1001 was calculated from the regional time-activity curve and the metabolite-corrected input function using Logan graphical analysis. ",
            "section": "Subjects",
            "paragraph_rank": 5,
            "section_rank": 3
        },
        {
            "text": "36,37) Blocking rates (%) by tropisetron or ondansetron were calculated for each ROI as 100\u00d7[(V T at baseline\u2212V T at loading)/V T at baseline]%.",
            "section": "Subjects",
            "paragraph_rank": 5,
            "section_rank": 3,
            "ref_spans": [
                {
                    "start": 0,
                    "end": 6,
                    "type": "bibr",
                    "text": "36,37)"
                }
            ]
        },
        {
            "text": "RESULTS",
            "section_rank": 4
        },
        {
            "text": "Representative V T images of [ 11 C]CHIBA-1001 before and after tropisetron (20 mg) and ondansetron (8 mg) loading are shown in Fig. 1. ",
            "section": "RESULTS",
            "paragraph_rank": 6,
            "section_rank": 4,
            "ref_spans": [
                {
                    "start": 128,
                    "end": 134,
                    "type": "figure",
                    "ref_id": "fig_1",
                    "text": "Fig. 1"
                }
            ]
        },
        {
            "text": "Radioactivity in the human brain after intravenous administration of [ 11 C]CHIBA-1001 was widely distributed throughout, consistent with our previous report using postmortem human brain tissues. ",
            "section": "RESULTS",
            "paragraph_rank": 6,
            "section_rank": 4
        },
        {
            "text": "38) A single administration of 20 mg tropisetron decreased the VT of [ 11 C] CHIBA-1001 in the brain (Fig. 1), whereas ondansetron (8 mg) had no effect. ",
            "section": "RESULTS",
            "paragraph_rank": 6,
            "section_rank": 4,
            "ref_spans": [
                {
                    "start": 0,
                    "end": 3,
                    "type": "bibr",
                    "ref_id": "b40",
                    "text": "38)"
                },
                {
                    "start": 101,
                    "end": 109,
                    "type": "figure",
                    "ref_id": "fig_1",
                    "text": "(Fig. 1)"
                }
            ]
        },
        {
            "text": "The mean blocking rates of the whole brain by 5 mg, 10 mg, and 20 mg tropisetron were 1.2\u00b10.02% (mean\u00b1SD, n=3), 7.6 \u00b10.03% (n=3), and 14.1\u00b10.02% (n=3), respectively. ",
            "section": "RESULTS",
            "paragraph_rank": 6,
            "section_rank": 4
        },
        {
            "text": "In contrast, the mean blocking rate of ondansetron of the whole brain was \u22120.4\u00b10.03% (n=3). ",
            "section": "RESULTS",
            "paragraph_rank": 6,
            "section_rank": 4
        },
        {
            "text": "As shown in Fig. 2, single administration of tropisetron blocked the binding of [ 11 C]CHIBA-1001 in the human brain in a dose-dependent manner, whereas a single administration of ondansetron had almost no effect. ",
            "section": "RESULTS",
            "paragraph_rank": 6,
            "section_rank": 4,
            "ref_spans": [
                {
                    "start": 12,
                    "end": 18,
                    "type": "figure",
                    "ref_id": "fig_2",
                    "text": "Fig. 2"
                }
            ]
        },
        {
            "text": "Furthermore, a significant (r= 0.979, p\uff1c0.001) positive correlation was observed between the plasma concentration of tropisetron and the administered dose of tropisetron (Fig. 3).",
            "section": "RESULTS",
            "paragraph_rank": 6,
            "section_rank": 4,
            "ref_spans": [
                {
                    "start": 170,
                    "end": 178,
                    "type": "figure",
                    "text": "(Fig. 3)"
                }
            ]
        },
        {
            "text": "DISCUSSION",
            "section_rank": 5
        },
        {
            "text": "The present study showed that a single oral administration of tropisetron, but not ondansetron, blocks the binding of [ 11 C]CHIBA-1001 in the human brain in a dose-dependent manner.   ",
            "section": "DISCUSSION",
            "paragraph_rank": 7,
            "section_rank": 5
        },
        {
            "text": ". 3. Correlations between the administered dose of tropisetron and the plasma concentration of tropisetron. There is a significant (r=0.979, p\uff1c0.001) positive correlation between the administered dose of tropisetron and plasma concentration. Plasma samples were taken 3-3.5 hours after administration of tropisetron.",
            "section": "DISCUSSION",
            "paragraph_rank": 7,
            "section_rank": 5,
            "ref_spans": [
                {
                    "start": 0,
                    "end": 3,
                    "type": "figure",
                    "text": ". 3"
                }
            ]
        },
        {
            "text": "Deficient inhibitory processing of the P50 auditory-evoked potential is a pathophysiological feature of schizophrenia. ",
            "section": "DISCUSSION",
            "paragraph_rank": 8,
            "section_rank": 5
        },
        {
            "text": "Several lines of evidence suggest that \u03b17nicotinic receptors play a critical role in this phenomenon. ",
            "section": "DISCUSSION",
            "paragraph_rank": 8,
            "section_rank": 5
        },
        {
            "text": "Previously, we reported that tropisetron improved deficient auditory inhibition processing in DBA/2 mice and that the improvement by tropisetron could be antagonized by co-administration of the \u03b17-nAChR antagonist MLA. ",
            "section": "DISCUSSION",
            "paragraph_rank": 8,
            "section_rank": 5
        },
        {
            "text": "39) Furthermore, we also reported that phencyclidine (PCP)induced cognitive deficits in mice improve by subsequent subchronic administration of tropisetron, but not ondansetron, and that the improvement was antagonized by co-administration of MLA. ",
            "section": "DISCUSSION",
            "paragraph_rank": 8,
            "section_rank": 5,
            "ref_spans": [
                {
                    "start": 0,
                    "end": 3,
                    "type": "bibr",
                    "ref_id": "b42",
                    "text": "39)"
                }
            ]
        },
        {
            "text": "40) These preclinical findings suggest that tropisetron could improve abnormal auditory sensory gating and PCP-induced cognitive deficits in mice via \u03b17-nAChRs. ",
            "section": "DISCUSSION",
            "paragraph_rank": 8,
            "section_rank": 5,
            "ref_spans": [
                {
                    "start": 0,
                    "end": 3,
                    "type": "bibr",
                    "ref_id": "b43",
                    "text": "40)"
                }
            ]
        },
        {
            "text": "39,40) In clinical studies, we reported that a single oral administration of tropisetron (10 mg) improved deficits in P50 suppression in non-smoking patients with schizophrenia. ",
            "section": "DISCUSSION",
            "paragraph_rank": 8,
            "section_rank": 5,
            "ref_spans": [
                {
                    "start": 0,
                    "end": 3,
                    "type": "bibr",
                    "ref_id": "b42",
                    "text": "39,"
                },
                {
                    "start": 3,
                    "end": 6,
                    "type": "bibr",
                    "ref_id": "b43",
                    "text": "40)"
                }
            ]
        },
        {
            "text": "41) A recent randomized, placebo-controlled study of tropisetron showed that tropisetron (10 mg/day for 8 weeks) significantly improved auditory sensory gating P50 deficits and attentional deficits in non-smoking patients with schizophrenia. ",
            "section": "DISCUSSION",
            "paragraph_rank": 8,
            "section_rank": 5,
            "ref_spans": [
                {
                    "start": 0,
                    "end": 3,
                    "type": "bibr",
                    "ref_id": "b44",
                    "text": "41)"
                }
            ]
        },
        {
            "text": "42) Taken together with these previous findings, the present study shows that tropisetron may bind to \u03b17-nAChRs in the human brain after a single oral administration, suggesting the role of \u03b17-nAChRs in the mechanisms of its efficacy. ",
            "section": "DISCUSSION",
            "paragraph_rank": 8,
            "section_rank": 5,
            "ref_spans": [
                {
                    "start": 0,
                    "end": 3,
                    "type": "bibr",
                    "ref_id": "b45",
                    "text": "42)"
                }
            ]
        },
        {
            "text": "Of all ROIs, the highest blocking rate, approximately 22.6%, was seen in the cerebellum by 20 mg of tropi-setron. ",
            "section": "DISCUSSION",
            "paragraph_rank": 8,
            "section_rank": 5
        },
        {
            "text": "The dose-blocking rate relationship of tropisetron did not follow the simplified Hill equation of occupancy =Occupancy max [F/(F\uff0bED 50 )], where Occupancy max refers to maximal occupancy, F is dose or plasma concentration of tropisetron, and ED50 is the plasma tropisetron level resulting in 50% maximal occupancy. ",
            "section": "DISCUSSION",
            "paragraph_rank": 8,
            "section_rank": 5
        },
        {
            "text": "This suggests that 20 mg of tropisetron is not sufficient to saturate the blocking of [ 11 C]CHIBA-1001. ",
            "section": "DISCUSSION",
            "paragraph_rank": 8,
            "section_rank": 5
        },
        {
            "text": "Increasing the dose of tropisetron may reveal higher blocking rates, but we avoided this for safety reasons. ",
            "section": "DISCUSSION",
            "paragraph_rank": 8,
            "section_rank": 5
        },
        {
            "text": "The dose of ondansetron was limited to 8 mg due to the same safety reasons.",
            "section": "DISCUSSION",
            "paragraph_rank": 8,
            "section_rank": 5
        },
        {
            "text": "[ 11 C]CHIBA-1001 PET data were well described with a one-tissue two-compartment model, but the direct derivation of the specific binding potential (BPND) as BPND=k3/ k 4 in a two-tissue three-compartment model was unstable (data not shown). ",
            "section": "DISCUSSION",
            "paragraph_rank": 9,
            "section_rank": 5
        },
        {
            "text": "Furthermore, as the radioactivity after administration of [ 11 C]CHIBA-1001 was widely distributed throughout the human brain, there was no reference region for the indirect derivation of BP ND . ",
            "section": "DISCUSSION",
            "paragraph_rank": 9,
            "section_rank": 5
        },
        {
            "text": "Therefore, we used VT for quantitative analysis of [",
            "section": "DISCUSSION",
            "paragraph_rank": 9,
            "section_rank": 5
        },
        {
            "text": "11 C]CHIBA-1001",
            "section": "DISCUSSION",
            "paragraph_rank": 10,
            "section_rank": 5
        },
        {
            "text": "PET data in this study. ",
            "section": "DISCUSSION",
            "paragraph_rank": 11,
            "section_rank": 5
        },
        {
            "text": "Although CHIBA-1001 is devoid of activity (inhibition lower than 50%) for the 28 standard receptor-binding profile, 27) we recently reported that the non-specific binding of [ 3 H]CHIBA-1001 is relatively high in membranes from postmortem human brain samples. ",
            "section": "DISCUSSION",
            "paragraph_rank": 11,
            "section_rank": 5,
            "ref_spans": [
                {
                    "start": 116,
                    "end": 119,
                    "type": "bibr",
                    "ref_id": "b28",
                    "text": "27)"
                }
            ]
        },
        {
            "text": "38) In the present study, the exact occupancy of \u03b17-nAChR by tropisetron could not be determined because V T , which is used for quantitative analysis of [ 11 C]CHIBA-1001 PET data, includes both specific and nonspecific binding. ",
            "section": "DISCUSSION",
            "paragraph_rank": 11,
            "section_rank": 5,
            "ref_spans": [
                {
                    "start": 0,
                    "end": 3,
                    "type": "bibr",
                    "ref_id": "b40",
                    "text": "38)"
                }
            ]
        },
        {
            "text": "Despite these limitations, this study suggests that [ 11 C]CHIBA-1001 may be a useful PET ligand for blocking studies of \u03b17-nAChR drugs in the human brain, particularly because more suitable PET ligands for human study are not currently available.",
            "section": "DISCUSSION",
            "paragraph_rank": 11,
            "section_rank": 5
        },
        {
            "text": "In conclusion, the present study showed that a single oral administration of tropisetron, but not ondansetron, blocked the binding of [ 11 C]CHIBA-1001 in the human brain and also suggests that [",
            "section": "DISCUSSION",
            "paragraph_rank": 12,
            "section_rank": 5
        },
        {
            "text": "11 C]CHIBA-1001 may be a useful PET ligand for blocking studies of \u03b17-nAChRs in the human brain, although [ 11 C]CHIBA-1001 exhibits a high level of non-specific binding in the human brain. ",
            "section": "DISCUSSION",
            "paragraph_rank": 13,
            "section_rank": 5,
            "ref_spans": [
                {
                    "start": 106,
                    "end": 113,
                    "type": "bibr",
                    "text": "[ 11 C]"
                }
            ]
        },
        {
            "text": "Therefore, the development of novel PET ligands with low non-specific binding will be necessary.",
            "section": "DISCUSSION",
            "paragraph_rank": 13,
            "section_rank": 5
        },
        {
            "text": "[ 11 C",
            "section_rank": 6
        },
        {
            "text": "]CHIBA-1001 and PET Each volunteer participated in two [ 11 C",
            "section": "[ 11 C",
            "paragraph_rank": 14,
            "section_rank": 6
        },
        {
            "text": "Fig. 1 .",
            "section_rank": 7
        },
        {
            "text": "Total distribution volume (VT) images of [ 11 C]CHIBA-1001 positron emission tomography before and after single oral administration of tropisetron or ondansetron. ",
            "section": "Fig. 1 .",
            "paragraph_rank": 15,
            "section_rank": 7
        },
        {
            "text": "The upper pair represents VT images at baseline (left) and at tropisetron (20 mg)-loading (right) in the same subject. ",
            "section": "Fig. 1 .",
            "paragraph_rank": 15,
            "section_rank": 7
        },
        {
            "text": "The lower pair shows VT images at baseline (left) and ondansetron (8 mg)-loading (right) in another subject.",
            "section": "Fig. 1 .",
            "paragraph_rank": 15,
            "section_rank": 7
        },
        {
            "text": "Fig. 2 .",
            "section_rank": 8
        },
        {
            "text": "Blocking rates of [ 11 C]CHIBA-1001 by tropisetron and ondansetron. ",
            "section": "Fig. 2 .",
            "paragraph_rank": 16,
            "section_rank": 8
        },
        {
            "text": "The mean\u00b1standard deviation of three subjects for each dose is shown.",
            "section": "Fig. 2 .",
            "paragraph_rank": 16,
            "section_rank": 8
        },
        {
            "text": "Fig",
            "section_rank": 9
        },
        {
            "text": "Fig. 3. ",
            "section": "Fig",
            "paragraph_rank": 17,
            "section_rank": 9
        },
        {
            "text": "Correlations between the administered dose of tropisetron and the plasma concentration of tropisetron. ",
            "section": "Fig",
            "paragraph_rank": 17,
            "section_rank": 9
        },
        {
            "text": "There is a significant (r=0.979, p\uff1c0.001) positive correlation between the administered dose of tropisetron and plasma concentration. ",
            "section": "Fig",
            "paragraph_rank": 17,
            "section_rank": 9
        },
        {
            "text": "Plasma samples were taken 3-3.5 hours after administration of tropisetron.",
            "section": "Fig",
            "paragraph_rank": 17,
            "section_rank": 9
        },
        {
            "text": "Table 1 .",
            "section_rank": 10
        },
        {
            "text": "Affinities of tropisetron and ondansetron at 5-HT3 receptors, \u03b17-nAChRs, and \u03b14\u03b22nAChRs",
            "section": "Table 1 .",
            "paragraph_rank": 18,
            "section_rank": 10
        }
    ]
}